免疫原性细胞死亡及其在肝癌治疗应用中的研究进展  

Progress in Research on Immunogenic Cell Death and Its Application in Hepatocellular Carcinoma Therapy

作　　者：巩辰宇 谭凯 杜锡林 

机构地区：[1]西安医学院研究生工作部,陕西 西安 [2]空军军医大学唐都医院普外科,陕西 西安

出　　处：《临床医学进展》2024年第9期1025-1033,共9页Advances in Clinical Medicine

摘　　要：免疫原性细胞死亡(immunogenic cell death, ICD)在肝癌的治疗中有重要作用。机体发生ICD时,细胞分泌多种损伤相关分子模式(damage-associated molecular patterns, DAMPs),包括三磷酸腺苷(adenosine triphosphate, ATP)、钙网蛋白(calreticulin, CRT)、高迁移率族蛋白B1 (high mobility group box protein B1, HMGB1)、热休克蛋白(heat shock protein, HSP)和干扰素(Interferon, IFN)等。DAMPs通过各种模式识别受体吸引自然杀伤细胞、巨噬细胞、树突状细胞等免疫细胞,并促进其成熟、活化从而增强抗肿瘤免疫反应。目前诱导ICD治疗肝癌主要通过药物方式(化疗药物、靶向药物等)、生物方式(溶瘤病毒)及物理方式(纳米脉冲刺激、光动力疗法等)。本文就ICD的相关分子及在肝癌治疗中的研究进展作一综述,以期在临床上为肝癌患者的治疗提供一些有益参考。Immunogenic cell death (ICD) has an important role in the treatment of hepatocellular carcinoma. When ICD occurs in the body, cells secrete various damage-associated molecular patterns (DAMPs), and the major DAMPs include adenosine triphosphate (ATP), calreticulin (CRT), high mobility group box protein B1 (HMGB1), heat shock protein (HSP), and interferon (IFN), etc. DAMPs attract natural killer cells, macrophages, dendritic cells and other immune cells through various pattern recognition receptors, and promote their maturation and activation to enhance anti-tumor immune responses. Currently, the induction of ICD in hepatocellular carcinoma treatment is mainly done by pharmacological (chemotherapeutic drugs, targeted drugs, etc.), biological (oncolytic viruses), and physical (nano-pulse stimulation, photodynamic therapy, etc.) modalities. In this article, we present a review of the important molecules related to ICD and the research progress of induced ICD in hepatocellular carcinoma treatment, in order to help design more effective and precise strategies to treat hepatocellular carcinoma in the future.

关 键 词：肝细胞癌 免疫原性细胞死亡 三磷酸腺苷 钙网蛋白 高迁移率族蛋白B1 

分 类 号：R73[医药卫生—肿瘤]